PathAI, a global leader in AI-powered pathology, today announced it has applied its PathExplore panel of human interpretable features (HIFs) on publicly available samples from The Cancer Genome Atlas (TCGA), a comprehensive resource of oncology data containing genomic and outcomes data, along with associated H&E whole-slide images (WSIs). PathAI will make the HIFs from eight TCGA cancer types available for free as a data access program for academic researchers to perform independent research to support their own investigations.
Earlier this year, PathAI launched PathExplore, an AI-powered panel of HIFs offering unprecedented resolution of the tumor microenvironment (TME) from digitized H&E slides. Powered by artificial intelligence, PathExplore spatially characterizes the TME with single-cell resolution, giving researchers the ability to unlock insights on patient response, drug pathways, and potential novel biomarkers.
The ability to characterize and quantify histopathological features of the TME will enable new avenues of disease research, and may lead to promising new therapies. With this PathExplore HIF research data set, oncology researchers can analyze tissue compositions, cell populations, and how their quantities and spatial relationships correlate with molecular signatures, treatment response or prognostic outcomes.
This data set is the first of its kind: no other widely available quantitative, structured data set based on histopathology exists. The features are standardized across indications, so researchers can glean new insights into the common or distinct TME characteristics of each tumor type or patient subset. Adding structured and standardized pathology data to TCGA enables a new set of multi-model investigations for researchers to pursue, all while lowering the barrier to integrating pathology image data into biomedical research that previously had been restricted to labs that had access to manual pathology analysis.
The TME has been a challenge to fully investigate due to the sheer amount of spatially distributed information contained within it, said Mike Montalto, PathAIs chief scientific officer. Pathologists can assess the specimens and try to estimate how certain cell or tissue growth patterns are present in each patient, but they cannot exhaustively enumerate each and every relevant cell type under the microscope. That is what our PathExplore products provide – they not only accurately identify where each cell is located, but they provide structured and standardized feature tables that can enable next generation pathology research to be performed.
To learn more about PathAIs PathExplore HIF research data set and apply for access, please reach out to email@example.com. If approved, there is no cost to academic researchers to access and use these data sets. PathExplore HIFs are for research use only and not for use in diagnostic procedures. Biopharma industry partners interested in purchasing a license to access PathExplore TCGA HIFs may reach out to firstname.lastname@example.org for more information.
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases.
PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com.
SVM Public Relations and Marketing Communications
View source version on newsdirect.com: https://newsdirect.com/news/pathai-launches-its-ai-powered-pathexplore-data-access-program-for-academic-researchers-299388519
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Scotland News journalist was involved in the writing and production of this article.